The Luvmeebody Wellnessclub/Blogs/Articles

For months, GLP-1 receptor agonists like semaglutide and liraglutide have dominated wellness conversations, primarily for their significant effects on weight management. This class of medications has offered a new tool for individuals navigating obesity. Now, a profound shift is underway, moving the focus from the number on the scale to the health of the heart.

A groundbreaking clinical trial and a subsequent landmark decision by the U.S. Food and Drug Administration (FDA) have officially expanded the role of these medications, cementing their status as a critical intervention for cardiovascular risk reduction in specific populations. This evolution reframes obesity not merely as a weight issue, but as a complex metabolic condition with far-reaching implications for long-term health.

What the Research Shows

GLP-1 receptor agonists are a class of medications that mimic the action of a natural gut hormone, glucagon-like peptide-1 [3]. This hormone plays a key role in managing blood sugar, slowing digestion, and signaling fullness to the brain, which contributes to their effectiveness in weight management and diabetes care [6]. For years, scientists have suspected these effects could also translate into cardiovascular protection, but definitive, large-scale evidence in people without diabetes was needed.

That evidence arrived with the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial. This large-scale, randomized, placebo-controlled study involved over 17,600 participants who had pre-existing cardiovascular disease and either overweight or obesity, but did not have diabetes [2]. The results, published in the New England Journal of Medicine, were significant.

The study found that treatment with semaglutide (2.4 mg) led to a 20% reduction in the risk of major adverse cardiovascular events (defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke) compared to those who received a placebo [2]. This demonstrated a clear cardiovascular benefit independent of the medication’s use in diabetes.

Based on these robust findings, the FDA took a decisive step. In March 2024, the agency officially approved a new indication for Wegovy (the brand name for semaglutide 2.4 mg) to be used to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [1]. This was the first time a weight-loss medication has received such an indication.

Experts suggest the benefits likely stem from a combination of effects. While weight loss itself is helpful, these medications also appear to improve traditional cardiovascular risk factors, including blood pressure, lipids (cholesterol), and markers of inflammation [4, 5].

What This Means for Everyday Wellness

The findings from the SELECT trial and the resulting FDA approval represent a paradigm shift in how we approach the treatment of obesity. It reinforces the understanding of obesity as a chronic disease that directly contributes to life-threatening cardiovascular events [4]. For individuals with a history of heart issues, this research provides a new, evidence-based avenue for risk reduction beyond existing standard-of-care treatments.

This development highlights the importance of focusing on comprehensive metabolic health. Metabolic wellness isn’t just about weight; it’s a constellation of factors including blood pressure, blood sugar control, and cholesterol levels [5]. The new indication for semaglutide underscores that addressing weight within a medical context can have a powerful, protective effect on the entire cardiovascular system.

It is essential to note that these medications are not a standalone solution. The FDA approval specifies that the medication should be used as an adjunct to a reduced-calorie diet and increased physical activity [1]. In the SELECT trial, all participants received comprehensive medical care for their cardiovascular conditions alongside the study drug or placebo [2]. This reinforces the core principle of holistic wellness: pairing medical innovation with foundational lifestyle habits.

A conversation with a trusted healthcare provider is the critical first step for anyone who believes they may be a candidate for this therapy. They can assess your individual health profile, including cardiovascular history, and discuss the potential benefits and known side effects, such as the commonly reported gastrointestinal issues [2].

A Gentle Reminder

The journey to wellness is deeply personal. This evolving research provides us with new tools and a deeper understanding of metabolic health, but it is best navigated in partnership with your healthcare team to find a path that is right for your unique body and circumstances.

Sources and Resources

1. [1] U.S. Food and Drug Administration (FDA). FDA Approves First Treatment to Reduce Risk of Heart Attack, Stroke and Cardiovascular Death in Adults with Cardiovascular Disease and Either Obesity or Overweight (2024-03-08). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-heart-attack-stroke-and-cardiovascular-death-adults
2. [2] The New England Journal of Medicine. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023-11-11). https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
3. [3] Johns Hopkins Medicine. GLP-1 Agonists: A ‘Game Changer’ for Weight Loss or Too Good to Be True? (2023). https://www.hopkinsmedicine.org/health/wellness-and-prevention/glp-1-agonists-a-game-changer-for-weight-loss-or-too-good-to-be-true
4. [4] JAMA. Unpacking the SELECT Trial—A New Era in Obesity Treatment (2023-11-11). https://jamanetwork.com/journals/jama/fullarticle/2811728
5. [5] National Heart, Lung, and Blood Institute (NIH). What Is Metabolic Syndrome? (2023-03-24). https://www.nhlbi.nih.gov/health/metabolic-syndrome
6. [6] MedlinePlus (NIH). GLP-1 Agonists (2024). https://medlineplus.gov/druginfo/medclass/glp-1-agonists.html

Educational disclaimer: This article is for general wellness education only. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. It is not a substitute for consultation with a qualified healthcare professional. Always speak with your clinician before starting or changing any medication, supplement, or wellness routine, especially if you are pregnant, nursing, taking medication, or managing a health condition.

Explore more guided wellness at
The Luvmee Body Wellness Club.